Age (years) | 66 (60–72) |
Sex | |
Female | 12 (46%) |
Male | 14 (54%) |
Histology | |
Adenocarcinoma | 26 (100%) |
Tumor location | |
Head | 21 (81%) |
Body | 4 (15%) |
Tail | 1 (4%) |
Resectability status (at diagnosis) | |
Borderline resectable | 11 (42%) |
Locally advanced | 15 (58%) |
Induction chemotherapy | |
FOLFRINOX | 16 (62%) |
Gem/Abraxane | 6 (23%) |
FOLFRINOX and Gem/Abraxane | 4 (15%) |
Time to progression (days) | 120 (60–180) |
Follow-up (days) | 200 (111–289) |